Difference between revisions of "Myeloproliferative neoplasms"

From Libre Pathology
Jump to navigation Jump to search
m (MPN vs MDS)
Line 1: Line 1:
'''Myeloproliferative neoplasms''', also '''myeloproliferative disorders''', are a group of indolent hematologic neoplasms characterized by clonal expansion of pluripotent hematopoietic progenitor.
'''Myeloproliferative neoplasms''', also '''myeloproliferative disorders''', are a group of indolent hematologic neoplasms characterized by clonal expansion of pluripotent hematopoietic progenitor.


These should '''not''' be confused with ''[[myelodysplastic syndromes]]'' (MDS).
These should '''not''' be confused with ''[[myelodysplastic syndromes]]'' (MDS), the main difference is that MPNs produce functional haematological cells detectable on a complete blood count, whereas in MDS, hematopoisis is ineffective and is characterised by cytopenias.


==Grouping==
==Grouping==
They include the following:<ref name=pmid15781101>{{cite journal |author=Baxter EJ, Scott LM, Campbell PJ, ''et al.'' |title=Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders |journal=Lancet |volume=365 |issue=9464 |pages=1054–61 |year=2005 |pmid=15781101 |doi=10.1016/S0140-6736(05)71142-9 |url=}}</ref>
They include the following:<ref name=pmid15781101>{{cite journal |author=Baxter EJ, Scott LM, Campbell PJ, ''et al.'' |title=Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders |journal=Lancet |volume=365 |issue=9464 |pages=1054–61 |year=2005 |pmid=15781101 |doi=10.1016/S0140-6736(05)71142-9 |url=}}</ref>
*Polycythemia vera.
*[[Chronic myeloid leukemia]]
*Essential thrombocythemia.
*[[Polycythemia vera]]
*Idiopathic myelofibrosis.
*[[Essential thrombocythemia]].
*[[Idiopathic myelofibrosis]].


==Clinic==
==Clinic==
* moderate to severe anemia
* moderate to severe anemia (in cases where the erythrocytosis is not a feature)
* pale skin
* pale skin
* fatigue
* fatigue

Revision as of 16:25, 26 May 2018

Myeloproliferative neoplasms, also myeloproliferative disorders, are a group of indolent hematologic neoplasms characterized by clonal expansion of pluripotent hematopoietic progenitor.

These should not be confused with myelodysplastic syndromes (MDS), the main difference is that MPNs produce functional haematological cells detectable on a complete blood count, whereas in MDS, hematopoisis is ineffective and is characterised by cytopenias.

Grouping

They include the following:[1]

Clinic

  • moderate to severe anemia (in cases where the erythrocytosis is not a feature)
  • pale skin
  • fatigue
  • prolonged bleeding
  • enlarged spleen
  • increased clotting

Polycythemia vera

  • ICD-O: 9950/3
  • Median age: 60 years.
  • Median survival: >10years.
  • Typical course:
    • Prodromal stadium: Mild erythrocytosis.
    • Polycythemic phase: Incereased RBC count.
    • Post-polycythemic ("spent") phase: Ineffective hematopoiesis, bone marrow fibrosis.
  • Transformation in AML possible (2-3%).

Morphology

  • Panmyelosis.
  • Many megakaryocytes in bone marrow section.
  • Increased cellularity of bone marrow (35-100%).
  • Teardrop-RBC cells (dacryocytes) in late stage.
  • Fibrosis (reticulin stain).

Essential thrombocythaemia

  • ICD-O: 9962/3
  • Median age: 55 years.
  • Mostly asymptomatic.
  • Indolent course, long-term survival. Life-threatening thromboembolitic epsisodes.

Morphology

  • Thrombocytosis.
  • Bone marrow normo- to slightly hypercellular.
  • Large megakaryocytes in bone-marrow.
  • Usually no BM fibrosis.

Images

Molecular

  • BCR-ABL1 negative (DDx: Leukemia (BCR-ABL1 positive))
  • A specific JAK2 mutation (Val617Phe) in seen in a group of patients.[1][2]
    • In JAK2-negative cases, CALR or MPL-Mutations are often found.[3]

See also

References

  1. 1.0 1.1 Baxter EJ, Scott LM, Campbell PJ, et al. (2005). "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders". Lancet 365 (9464): 1054–61. doi:10.1016/S0140-6736(05)71142-9. PMID 15781101.
  2. Steensma DP, Dewald GW, Lasho TL, et al. (August 2005). "The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes". Blood 106 (4): 1207–9. doi:10.1182/blood-2005-03-1183. PMC 1895198. PMID 15860661. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895198/.
  3. Nangalia, J.; Green, TR. (Dec 2014). "The evolving genomic landscape of myeloproliferative neoplasms.". Hematology Am Soc Hematol Educ Program 2014 (1): 287-96. doi:10.1182/asheducation-2014.1.287. PMID 25696868.